UBS Group’s Accelerate Diagnostics AXDX Stock Holding History

UBS Group’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,000	Closed	-$860K	–	7625
2015 Q4	$860K	Buy	+4,000	New	+$730K	﹤0.01%	3527
2015 Q2	–	Sell	-40	Closed	-$9K	–	8472
2015 Q1	$9K	Sell	40 -30	-43%	-$6.27K	﹤0.01%	7702
2014 Q4	$13K	Buy	+70	New	+$15K	﹤0.01%	8135

Other funds holding AXDX

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BCWM

Bartlett & Co Wealth Management Cincinnati, Ohio $7.99B AUM 20.76% 1-Year Est. Return

UBS Group's AXDX Position: Q2 2025 in Review

UBS Group sold out of Accelerate Diagnostics (AXDX) in Q2 2025, closing a stake of 20 shares — an estimated $14 sold.

UBS Group first reported a position in AXDX in Q4 2014 and held it in 42 quarters. The position peaked at $4.95M in Q4 2017. 3 funds tracked by Wall St. Rank hold AXDX as of Q2 2025.

UBS Group reported no remaining Accelerate Diagnostics position as of Q2 2025 after selling out during the quarter.
UBS Group sold 20 Accelerate Diagnostics shares in Q2 2025, an estimated $14.
UBS Group first reported a position in Accelerate Diagnostics in Q4 2014 and held it in 42 quarters.
UBS Group's Accelerate Diagnostics position peaked at $4.95M in Q4 2017.
3 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2025.

Based on UBS Group's 13F filing for Q2 2025, filed 14 Aug 2025.